Cardiovascular Research Institute

Search results

• What’s the Damage With Long COVID? Advanced Imaging Reveals Clues

  Trivieri, M.

  27/05/25

  1 item of Media coverage

  Press/Media

• Weekly: Tourmaline Bio (TRML: $15.32) slides 7.5%, 2 weeks' volume in a week; -$1.24 [7.5%] Vol Index 1.8 [1 is avg]

  Fuster, V. & Bhatt, D. L.

  24/05/25

  1 item of Media coverage

  Press/Media

• Two-bagger Corcept Therapeutics (CORT: $78.69) climbs 4.8%; +$3.61 [4.8%]

  Fuster, V. & Bhatt, D. L.

  24/05/25

  1 item of Media coverage

  Press/Media

• Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High-Sensitivity C-reactive Protein and Chronic Kidney Disease

  Fuster, V. & Bhatt, D. L.

  21/05/25

  1 item of Media coverage

  Press/Media

• Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug in Patients with Elevated High Sensitivity C reactive Protein and Chronic Kidney Disease

  Fuster, V. & Bhatt, D. L.

  20/05/25 → 21/05/25

  3 items of Media coverage

  Press/Media

• Tourmaline Bio to Presented Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

  Fuster, V. & Bhatt, D. L.

  20/05/25

  1 item of Media coverage

  Press/Media

• Tourmaline Bio Announces Positive Topline Results From The Ongoing Phase 2 TRANQUILITY Trial Evaluating Pacibekitug In Patients With Elevated High-Sensitivity C-Reactive Protein And Chronic Kidney Disease

  Fuster, V. & Bhatt, D. L.

  20/05/25

  7 items of Media coverage

  Press/Media

• Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

  Fuster, V. & Bhatt, D. L.

  20/05/25

  2 items of Media coverage

  Press/Media

• To Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

  Fuster, V. & Bhatt, D. L.

  20/05/25

  1 item of Media coverage

  Press/Media

• Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

  Fuster, V. & Bhatt, D. L.

  20/05/25

  1 item of Media coverage

  Press/Media

• Tourmaline Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

  Fuster, V. & Bhatt, D. L.

  20/05/25

  1 item of Media coverage

  Press/Media

• Study Results from Brigham and Women's Hospital Provide New Insights into Heart Attack [Sex Differences in the Association Between Lipoprotein(a) and Cardiovascular Outcomes: The MGB Lp(a) Registry]

  Bhatt, D. L.

  20/05/25

  1 item of Media coverage

  Press/Media

• Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

  Fuster, V. & Bhatt, D. L.

  19/05/25

  75 items of Media coverage

  Press/Media

• Two-bagger Corcept Therapeutics (CORT: $75.08) gains 7%; +$4.85 [6.9%]

  Fuster, V. & Bhatt, D. L.

  17/05/25

  1 item of Media coverage

  Press/Media

• Israeli PM Netanyahu: ethnic cleansing of Gaza is “inevitable” – War on Gaza Day 585

  Cohen, O.

  15/05/25

  1 item of Media coverage

  Press/Media

• Mount Sinai Researchers in Semifinals of $101 Million XPRIZE Healthspan, a Competition Seeking Innovative Approaches to Aging Well

  Merad, M., Marron, T., Fayad, Z. & Elahi, F.

  13/05/25

  1 item of Media coverage

  Press/Media

• A breakthrough in regenerating insulin-producing cells for diabetes treatment

  García-Ocaña, A., Stanley, S. & Wang, P.

  13/05/25

  1 item of Media coverage

  Press/Media

• Reports Outline Cancer Gene Therapy Study Results from Icahn School of Medicine at Mount Sinai (Novel Artificial 5'UTR Increase Modified mRNA Translation When Injected into Mouse Heart)

  DuBois, N., Swirski, F. & Zangi, L.

  12/05/25

  1 item of Media coverage

  Press/Media

• Mount Sinai Researchers In Semifinals Of $101 Million XPRIZE Healthspan, A Competition Seeking Innovative Approaches To Aging Well

  Merad, M., Marron, T., Fayad, Z. & Elahi, F.

  12/05/25

  24 items of Media coverage

  Press/Media

• Weekly: Tourmaline Bio (TRML: $15.10) shares post worst week in five weeks; -$1.20 [7.4%]

  Bhatt, D. L.

  10/05/25

  1 item of Media coverage

  Press/Media

• HMN 2025: How New gene is linked to extreme circumstances of Fanconi anemia

  Gelb, B. & Schindler, D.

  10/05/25

  1 item of Media coverage

  Press/Media

• Weekly: Corcept Therapeutics (CORT: $70.23) drops 3.5% on firm volume; -$2.54 [3.5%]

  Fuster, V. & Bhatt, D. L.

  10/05/25

  1 item of Media coverage

  Press/Media

• Long COVID tied to long-term changes in heart and lungs leading to cardiac and pulmonary diseases: Study

  Trivieri, M., Putrino, D. & Fayad, Z.

  9/05/25

  1 item of Media coverage

  Press/Media

• Corcept Therapeutics MCap surges $2.3 billion (43%) in 2025, highest in Medical/Drugs sector

  Fuster, V. & Bhatt, D. L.

  9/05/25

  1 item of Media coverage

  Press/Media

• Reports Summarize Opioids Research from Icahn School of Medicine at Mount Sinai (Peripheral Blood Cytokines as Markers of Longitudinal Change in White Matter Microstructure Following Inpatient Treatment for Opioid Use Disorders)

  King, S., Cathomas, F., Ceceli, A., Roussos, P., Alia-Klein, N., Goldstein, R. & Russo, S.

  8/05/25

  1 item of Media coverage

  Press/Media